$NRX Pharmaceuticals (NRXP.US)$ NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement Tuesday, 21st January at 8:02 am • Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement • Nasdaq stated that the matter is now closed WILMINGTON, Del., Jan. 21, 2025 /PR...
$NRX Pharmaceuticals (NRXP.US)$ HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel Tuesday, 14th January at 8:03 am "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field Kadima Neuropsychiatry Institute identified as p...
$NRX Pharmaceuticals (NRXP.US)$Reuters· 1 min ago NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces It Has Filed an Application With Nasdaq to Uplist to the Nasdaq Global Market From the Nasdaq Capital Market
$NRX Pharmaceuticals (NRXP.US)$ NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market Monday, 13th January at 8:04 am • Management believes uplisting has the potential to provide shareholders with improved liquidity • Requires NRx Pharmaceuticals to meet certain listing requirements • Company has advised NASDAQ that current shares outstanding is 15.7 million WILMINGTON, Del., Jan. 13, 2...
$NRX Pharmaceuticals (NRXP.US)$ HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco Tuesday, 7th January at 8:07 am The Keynote Address, entitled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD," will be ...
$NRX Pharmaceuticals (NRXP.US)$ HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations Monday, 6th January at 10:16 am Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 million in Series A Preferred Stock in HOP...
1
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
NRX Pharmaceuticals Stock Forum
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
Tuesday, 21st January at 8:02 am
• Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement
• Nasdaq stated that the matter is now closed
WILMINGTON, Del., Jan. 21, 2025 /PR...
FDA Approval scheduled on June 30th 2025
FDA Calendar – FDA Tracker
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
Tuesday, 14th January at 8:03 am
"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta
David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field
Kadima Neuropsychiatry Institute identified as p...
NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces It Has Filed an Application With Nasdaq to Uplist to the Nasdaq Global Market From the Nasdaq Capital Market
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market
Monday, 13th January at 8:04 am
• Management believes uplisting has the potential to provide shareholders with improved liquidity
• Requires NRx Pharmaceuticals to meet certain listing requirements
• Company has advised NASDAQ that current shares outstanding is 15.7 million
WILMINGTON, Del., Jan. 13, 2...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
Tuesday, 7th January at 8:07 am
The Keynote Address, entitled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD," will be ...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
Monday, 6th January at 10:16 am
Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations.
Purchase of $25 million in Series A Preferred Stock in HOP...
No comment yet